Clinical trials: Resectable Lung Non-Small Cell Carcinoma
Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
This phase II trial tests the effect of atezolizumab given with usual chemotherapy during radiation therapy in treating patients with superior sulcus non-small cell lung cancer.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Superior Sulcus Lung Carcinoma
- Trial name
- NCT04989283
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 46 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer
Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer
This is a randomized, open label study designed to evaluate the efficacy and safety of neoadjuvant PD-1 antibody plus chemotherapy followed by surgery in resectable stage IIIA-N2 non-small cell lung cancer.
- Trial name
- NCT04422392
- Testing
- Carboplatin, Pemetrexed or Nab-paclitaxel, PD-1 antibody
- Where
- 8 sites in China
- Volunteers
- 93 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-small Cell Lung Cancer, Radiation Therapy
Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma
The purpose of this study is to establish on the market and to clinically evaluate a new strategy of treatment for patients with locally advanced non-small cell lung cancer using deformable repositioning of 4D imaging.
- Conditions
- Non-small Cell Lung Cancer, Radiation Therapy, Locally Advanced Disease, Non-metastatic Disease
- Trial name
- midP (NCT01635270)
- Testing
- mid-position radiation strategy, ITV
- Where
- France
- Volunteers
- 54 people
- Sponsor
- Centre Leon Berard
Carcinoma, Non-Small-Cell Lung
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab.
- Trial name
- NCT06623422
- Testing
- Pembrolizumab, Cisplatin, Carboplatin
- Where
- 245 sites in United States, Argentina and 29 more
- Volunteers
- 680 people
- Sponsor
- Merck Sharp & Dohme LLC
Resectable Locally Advanced Non-small Cell Lung Cancer
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
This is a multicenter, randomized, open label, phase II study.
- Trial name
- ALTER-L043 (NCT04846634)
- Testing
- Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel, Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel, Penpulimab+Anlotinib
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Small Cell Lung Cancer
Prevention of Tumor Spread Due to Lung Cancer Surgery
This study will investigate operative techniques to reduce the risk of tumor spread as a result of lung cancer surgery. Recent studies indicate that tumor cells may be released into the bloodstream due to handling of the lung…
- Trial name
- NCT00341380
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Resectable Non-small Cell Lung Cancer
An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany
The purpose of this observational study is to collect and evaluate real-world data to assess the effectiveness of neoadjuvant nivolumab when given in combination with platinum-based chemotherapy in participants with early-stage…
- Trial name
- NENI (NCT06169956)
- Testing
- Neoadjuvant nivolumab in combination with platinum-based chemotherapy
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Non-Small-Cell Lung
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
This is a phase II, single institution trial for patients with clinical Stage IB-IIIA NSCLC (T1-3N0-2M0) who have resectable lung tumors.
- Trial name
- NCT00130780
- Testing
- Pre-surgical Treatment with Bevacizumab plus Chemotherapy, Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stage II-IIIB(N2) Non-small Cell Lung Cancer
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer
For resectable non-small cell lung cancer, neoadjuvant immunochemotherapy plus adjuvant immunotherapy or adjuvant immunochemotherapy is usually used in clinical practice.
- Trial name
- NCT06109402
- Testing
- TQB2450, Carboplatin, Pemetrexed
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery [neoadjuvant phase], followed by pembrolizumab alone after surgery…
- Trial name
- NCT03425643
- Testing
- Pembrolizumab, Cisplatin, Gemcitabine
- Where
- 227 sites in United States, Argentina and 23 more
- Volunteers
- 797 people
- Sponsor
- Merck Sharp & Dohme LLC
Resectable Colon Cancer, Resectable Non-small Cell Lung Cancer
Mechanism of Action Trial of ColoAd1
To assess the pattern of ColoAd1 viral delivery and viral expression within colon tumour tissue when administered by intra-tumoural injection or within colon, non-small cell lung, bladder and renal cell tumour tissues following…
- Conditions
- Resectable Colon Cancer, Resectable Non-small Cell Lung Cancer, Resectable Bladder Cancer, Resectable Renal Cell Carcinoma
- Trial name
- MOA (NCT02053220)
- Testing
- Colo-Ad1
- Where
- 2 sites in Spain
- Volunteers
- 17 people
- Sponsor
- Akamis Bio
NSCLC
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of H1 receptor antagonist (diphenhydramine) combined with toripalimab plus standard platinum-based chemotherapy in the perioperative setting in subjects with…
- Trial name
- NCT07358689
- Testing
- Toripalimab (240mg day1, Q3W*3cycle), Diphenhydramine, Platinum-based chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
IIIA Stage Non-small Cell Lung Cancer
Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer
Cancer has always been one of the leading causes of death in the world, and China is facing more and more severe challenges from cancer.
- Trial name
- Neo-Pre-IC (NCT04326153)
- Testing
- Sintilimab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Hospital of Jilin University
Lung Neoplasms, Quality of Life
Impact on Quality of Life From Multi-modality Lung Cancer
The investigators aim to explore how lung cancer patients and their family carers are affected by different types of cancer treatment. The investigators are focusing on a particular type of lung cancer called Stage III N2.
- Trial name
- PIONEER (NCT04540757)
- Testing
- Surgery, No surgery
- Where
- 2 sites in United Kingdom
- Volunteers
- 66 people
- Sponsor
- The Christie NHS Foundation Trust
NSCLC, Tislelizumab
Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
This study is a single-arm prospective clinical trial. The primary objective of the study is to explore the efficacy and safety of preoperative neoadjuvant therapy with Tislelizumab combined with Anlotinib and Nab-Paclitaxel in…
- Conditions
- NSCLC, Tislelizumab, Anlotinib, Nab-paclitaxel
- Trial name
- TitAN (NCT07089199)
- Testing
- neoadjuvant therapy, Surgery, Adjuvant therapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Qilu Hospital of Shandong University
NSCLC
Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2)
This is a single-center, single-arm, phase 2 trial evaluating the efficacy and safety of retlirafusp alfa combined with single-agent chemotherapy as neoadjuvant treatment for patients with resectable stage II-III EGFR/ALK…
- Trial name
- NCT07550920
- Testing
- Drug: Retlirafusp alfa, Drug: Single-agent Chemotherapy, Procedure: Radical Surgery
- Volunteers
- 18 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging
Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
Background: For patients with resectable stage III-N2b non-small cell lung cancer (NSCLC), optimal perioperative treatment strategies remain an area of active investigation.
- Conditions
- Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging, Lymphatic Metastasis
- Trial name
- NCT07538193
- Testing
- Iparomlimab and Tuvonralimab combined with Platinum-Based Chemotherapy (Pemetrexed/Carboplatin for Non-squamous; Nab-paclitaxel/Carboplatin for Squamous)
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Tang-Du Hospital
Non Small Cell Lung Cancer
A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer
This is a Phase II, single-Arm, prospective study of neoadjuvant Ensartinib for the treatment of patients with ALK positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer
- Trial name
- NCT05380024
- Testing
- Ensartinib
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non Small Cell Lung Cancer
Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB
This study aims to investigate the efficacy and safety of targeted therapy and chemotherapy±immunotherapy as neoadjuvant therapy in stage IIB-IIIB NSCLC patients.（observational study）
- Trial name
- NCT04197076
- Testing
- anti-PD-1 or anti-PD-L1, EGFR-TKI, ALK inhibitor, ROS1 inhibitor, investigator decided
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
NSCLC Stage II, NSCLC, Stage IIIA
Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB (T3N2 only) non-squamous Non-Small Cell Lung Cancer (NSCLC) to…
- Conditions
- NSCLC Stage II, NSCLC, Stage IIIA, NSCLC Stage IIIB
- Trial name
- iReP (NCT04865250)
- Testing
- Atezolizumab 1200 mg abs day 1 q22 (iv)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Heidelberg